JP2016504040A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504040A5
JP2016504040A5 JP2015551870A JP2015551870A JP2016504040A5 JP 2016504040 A5 JP2016504040 A5 JP 2016504040A5 JP 2015551870 A JP2015551870 A JP 2015551870A JP 2015551870 A JP2015551870 A JP 2015551870A JP 2016504040 A5 JP2016504040 A5 JP 2016504040A5
Authority
JP
Japan
Prior art keywords
chromatography
asa
purified recombinant
protein
ultrafiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015551870A
Other languages
English (en)
Japanese (ja)
Other versions
JP6427502B2 (ja
JP2016504040A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/010856 external-priority patent/WO2014110246A1/en
Publication of JP2016504040A publication Critical patent/JP2016504040A/ja
Publication of JP2016504040A5 publication Critical patent/JP2016504040A5/ja
Application granted granted Critical
Publication of JP6427502B2 publication Critical patent/JP6427502B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015551870A 2013-01-09 2014-01-09 アリールスルファターゼaの精製方法 Expired - Fee Related JP6427502B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750693P 2013-01-09 2013-01-09
US61/750,693 2013-01-09
PCT/US2014/010856 WO2014110246A1 (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018122837A Division JP2018171067A (ja) 2013-01-09 2018-06-28 アリールスルファターゼaの精製方法

Publications (3)

Publication Number Publication Date
JP2016504040A JP2016504040A (ja) 2016-02-12
JP2016504040A5 true JP2016504040A5 (enExample) 2017-02-16
JP6427502B2 JP6427502B2 (ja) 2018-11-21

Family

ID=50002885

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015551870A Expired - Fee Related JP6427502B2 (ja) 2013-01-09 2014-01-09 アリールスルファターゼaの精製方法
JP2018122837A Withdrawn JP2018171067A (ja) 2013-01-09 2018-06-28 アリールスルファターゼaの精製方法
JP2019174155A Withdrawn JP2020015750A (ja) 2013-01-09 2019-09-25 アリールスルファターゼaの精製方法
JP2021183082A Active JP7407161B2 (ja) 2013-01-09 2021-11-10 アリールスルファターゼaの精製方法
JP2023173170A Active JP7663649B2 (ja) 2013-01-09 2023-10-04 アリールスルファターゼaの精製方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018122837A Withdrawn JP2018171067A (ja) 2013-01-09 2018-06-28 アリールスルファターゼaの精製方法
JP2019174155A Withdrawn JP2020015750A (ja) 2013-01-09 2019-09-25 アリールスルファターゼaの精製方法
JP2021183082A Active JP7407161B2 (ja) 2013-01-09 2021-11-10 アリールスルファターゼaの精製方法
JP2023173170A Active JP7663649B2 (ja) 2013-01-09 2023-10-04 アリールスルファターゼaの精製方法

Country Status (12)

Country Link
US (3) US11407984B2 (enExample)
EP (1) EP2943568B1 (enExample)
JP (5) JP6427502B2 (enExample)
CN (4) CN119979504A (enExample)
AU (3) AU2014205441B2 (enExample)
BR (1) BR112015015948B1 (enExample)
CA (1) CA2896979C (enExample)
EA (1) EA030551B1 (enExample)
ES (1) ES2768261T3 (enExample)
HK (1) HK1214622A1 (enExample)
MX (2) MX372711B (enExample)
WO (1) WO2014110246A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
WO2014110246A1 (en) 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
CN108473558A (zh) * 2015-08-20 2018-08-31 豪夫迈·罗氏有限公司 Fkpa的纯化及其用于生产重组多肽的用途
CA3015685A1 (en) * 2016-03-16 2017-09-21 Phoenix Tissue Repair, Inc. Methods of purifying collagen 7
CN111065735B (zh) * 2017-08-31 2023-07-07 株式会社绿十字 用于纯化硫酸酯酶蛋白的方法
CA3086181A1 (en) * 2017-12-19 2019-06-27 Shire Human Genetic Therapies, Inc. Purified arylsulfatase a and compositons thereof
RU2020118032A (ru) * 2018-02-02 2022-03-02 Асераген, Инк. Способы лечения болезни фарбера
EP3774894A1 (en) 2018-04-12 2021-02-17 Amgen Inc. Methods for making stable protein compositions
CN112082832B (zh) * 2019-06-12 2022-03-29 华南理工大学 一种保存城市污水中硫酸酯结合体和葡萄糖苷醛酸结合体的方法
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
CN110632052A (zh) * 2019-10-25 2019-12-31 山西师范大学 土壤芳基硫酸酯酶活性的荧光光谱检测法
EP4072600A1 (en) * 2019-12-12 2022-10-19 Eli Lilly and Company Methods for viral inactivation by environmentally compatible detergents
CN112759643B (zh) * 2021-03-17 2023-05-30 华兰生物工程股份有限公司 一种血清白蛋白的脱脂方法
CN116693659B (zh) * 2023-07-11 2025-03-28 浙江大学 一种分离重组人血白蛋白的两步混合模式层析方法
EP4778935A1 (en) * 2025-01-15 2026-07-22 Sartorius Stedim Biotech GmbH Method for purifying a target product

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314997A (en) 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4315919A (en) 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
CA2041280A1 (en) * 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
ATE217799T1 (de) 1998-01-27 2002-06-15 Hemebiotech As Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
DK2270044T3 (en) 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
ID27417A (id) 1998-06-09 2001-04-05 Statens Seruminstitut Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
AU774603B2 (en) 1999-07-27 2004-07-01 Zymenex A/S Production of rhPBGD and new therapeutic methods for treating patients with acute intermittent porphyria (AIP) and other porphyric diseases
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1409695A2 (en) 2000-11-15 2004-04-21 Genzyme Corporation Expression system for recombinant proteins
WO2002099092A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
WO2002098455A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003002731A1 (en) 2001-06-29 2003-01-09 Hemebiotech A/S A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD)
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7118675B2 (en) 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
NZ576986A (en) * 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
PL1740204T3 (pl) 2004-04-01 2018-08-31 Chiesi Farmaceutici S.P.A. Lecznicze zastosowanie alfa-mannozydazy
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
NO347673B1 (no) 2006-04-04 2024-02-19 Takeda Pharmaceuticals Co En sammensetning som omfatter konsentrert polypeptide og bruk derav.
CN105646643A (zh) * 2008-10-29 2016-06-08 阿布林克斯公司 单域抗原结合性分子的纯化方法
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
JP6045493B2 (ja) * 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼaのcns送達の方法および組成物
CA2803166C (en) 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
WO2014110246A1 (en) 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a

Similar Documents

Publication Publication Date Title
EP2553095B1 (en) A process for purifying vitamin K dependent proteins such as coagulation factor IX
JP6836562B2 (ja) 治療タンパク質の精製方法
RU2647835C2 (ru) Стабилизатор для гиалуронидазы и жидкая композиция, содержащая гиалуронидазу
JP2022023225A (ja) アリールスルファターゼaの精製方法
WO2009156430A1 (en) A process of purifying coagulation factor viii
JP2014501251A (ja) トランスジェニックイネの子実からヒト血清アルブミンを精製する方法
JPH10506924A (ja) 動物性タンパク質を含まないエリトロポイエチンの製造のための方法
JP7086601B2 (ja) 組換えtnk-tpa(テネクテプラーゼ)の単離及び商業生産のための新規精製方法
US8476054B2 (en) Thrombin-like enzyme of Agkistrodon acutus
KR102528707B1 (ko) 고순도의 히알루로니다제 정제 방법
CN102924562A (zh) 一种人凝血因子ⅷ的干热处理稳定剂及其用途
JP2004535197A5 (enExample)
RS50960B (sr) Postupak za prečišćavanje eritropoetina
JPWO2008120801A1 (ja) アンチトロンビン組成物の製造方法
JP2019528242A5 (enExample)
US20140309408A1 (en) Method for purifying virus-like particles (vlp)
CN115386564B (zh) 一种尿激酶的纯化方法
HUE027724T2 (hu) Eljárás G-CSF tisztítására
CN104854122A (zh) 重组人半乳糖脑苷脂-β-半乳糖苷酶(rhGALC)的纯化
DE69719382T2 (de) VERFAHREN ZUR HERSTELLUNG VON rDSPA Alpha1
CN106011116A (zh) 一种人凝血酶的制备方法
CN105541994B (zh) 一种血小板生成素或其变体或衍生物的纯化方法
ES2625511T3 (es) Métodos para la purificación de arylsulfatasa A
JP2861655B2 (ja) ヒト尿性トリプシンインヒビター含有液状製剤及びその製造方法
JP2722140B2 (ja) ヒト尿性トリプシンインヒビターの製造方法